Latest from Mayo Clinic Cancer Center

Pashtoon M. Kasi, MD, discusses the recycling of therapies in patients with colorectal cancer (CRC).
 
Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the use of next-generation radiopharmaceuticals in prostate cancer.
Matthew P. Goetz, MD, Mayo Clinic, discusses the use of circulating tumor DNA in the phase III MONARCH-3 trial in hormone receptor–positive, HER2-negative breast cancer.
Matthew P. Goetz, MD, discusses the current treatment landscape for patients with estrogen receptor-positive, HER2-negative breast cancer who harbor ESR1 mutations, and provided an overview of the ELAINE trial.
Until strong findings emerged from the phase III PROfound study of PARP inhibitor olaparib (Lynparza) in patients with metastatic  castration-resistant prostate cancer, targeted therapy had an uncertain foothold in this tumor type. 
Parminder Singh, MD, discusses potential implications of the phase III IMvigor130 trial in advanced bladder cancer.
Alan H. Bryce, MD, discusses potential biomarkers of response to immunotherapy in prostate cancer.
Erik P. Castle, MD, discusses minimally invasive surgical approaches in renal cell carcinoma.
Publication Bottom Border
Border Publication
x